S&N settles whistleblower suit; LabCorp starts genomic diagnostics biz;

@FierceMedDev: Researchers develop self-powered pacemaker system based on automatic wristwatch. Article | Follow @FierceMedDev

@VarunSaxena2: Per Capita Medicare Spending Is Actually Falling. More from the NYT | Follow @VarunSaxena2

@MichaelGFierce: Artificial virus promises effective drug delivery and gene therapy. FierceDrugDelivery story | Follow @MichaelGFierce

@EmilyWFierce: Fingerprint scanning system could help track children's vaccinations in developing countries. More from MIT Technology Review | Follow @EmilyWFierce

> Smith & Nephew ($SNN) agreed to an $8.3 million settlement after a whistleblower exposed the company's attempts to pass off Malaysian-made products as manufactured in the U.S. Story

> LabCorp ($LH) launched a new business, Enlighten Health Genomic, to explore the diagnostic potential of next generation sequencing (NGS) technology. Release

> In a newly announced partnership, Covidien ($COV) is allowing Concord, NH-based health care company Geneia to sell its ZephyrLIFE remote patient monitoring services to patients with chronic illnesses. Story

Biotech News

@FierceBiotech: ICYMI: $GSK's new Boston collaboration chief goes 'anti-pharma' as he prowls for partners. Article | Follow @FierceBiotech

@JohnCFierce: In diabetes, everybody is trying to beat everybody on next steps. Which is why Afrezza continues to stand out as a lonely effort. | Follow @JohnCFierce

@DamianFierce: $KMDA won't let a little thing like missing its endpoints in PhII/III derail a regulatory filing. More | Follow @DamianFierce

@EmilyMFierce: FDA rushes J&J, NewLink Ebola vaccines to clinical trials. FierceVaccines story | Follow @EmilyMFierce

> Edison's orphan drug misses the mark in Phase II. Story

> Lilly claims another head-to-head victory over Lantus in PhIII diabetes showdown. Report

> J&J teams with Bavarian Nordic on an emergency Ebola vaccine program. More

Pharma News

@FiercePharma: Tops on FPMarketing Weds: Can Sanofi/Regeneron's new data one-up Amgen in megablockbuster PCSK9 field? Article | Follow @FiercePharma

@EricPFierce: Agents in EU seize €10M worth of counterfeit drugs, as well as cash and luxury cars, arrest a dozen. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Sanofi's dengue shot ups serotype 2 protection rate in final trial. FierceVaccines story | Follow @CarlyHFierce

> AstraZeneca pressed Obama for help resisting Pfizer's tax-cutting buyout bid. Article

> NICE slaps unusual rules on Alexion's pricey Soliris after atypical cost review. More

> Payers beware: Bristol-Myers prices PD-1 cancer med at $143,000 in Japan. Story

Vaccines News

> FDA rushes J&J, NewLink Genetics Ebola vaccines to clinical trials. Article

> Study: Old HIV pediatric vaccines might provide protection after all. Item

> Amid Bexsero negotiations, Novartis medical director slams U.K. vaccine assessment system. More

> Sanofi's dengue shot ups serotype 2 protection rate in final trial. Story

> Amgen submits melanoma-fighter T-Vec to EMA on the heels of its FDA filing. Report

Pharma Manufacturing News

> Theratechnologies returns HIV product Egrifta to U.S. Item

> Wockhardt expects to resolve most FDA concerns within the year. Report

> China sweeps up gang that made and sold 90M toxic capsules. More

> Actavis production not meeting demand for new version of Alzheimer's drug. Story

> Xellia lays out $100M expansion plan for new U.S. facility. Article

Suggested Articles

Qiagen launched a one-stop shop compiling publicly available genomic data, scientific literature and phenotypic information on potential superbugs.

Adaptive Biotechnologies is planning a $200 million IPO to help power its sequencing tests aimed at the body’s immune system and related therapies.

Abbott’s new diabetes test provides A1c results in three minutes, allowing clinicians to develop care plans within a single office visit.